Mobilizing the Supercharged Immune Armies Within

Explore More

Our Marching Orders are Simple

To combat disease, we are armed with a special weapon: AVM0703. AVM0703 is a purer and loaded formulation of dexamethasone which has been used at lower doses since 1958 for other purposes. Our supra-pharmacologic dose has a novel mechanism of action (MOA) to mobilize the body’s own natural supercharged immune cells that are ten times more activated than ordinary immune cells.

AVM0703 has activity in mouse models even against aggressive, impossible to cure cancer models. Preclinical studies show dramatic tumor reduction with supercharged NKT (Natural Killer T Cells) which are tenfold more efficient in killing tumors than normal NKT cells. Used as adjunctive therapy with common chemotherapies, AVM0703 could also enhance outcomes and minimize the needed toxic chemotherapy dosage.

Cancer Infectious Disease Leadership

AVM0703 could be the first choice for no-option cancer, autoimmunity, and infectious disease

Learn Why

Our Mission

Our passion is to deliver drugs that work rapidly and that are safe, effective, and affordable, to treat serious worldwide illness like cancer, autoimmunity, and life-altering infectious disease. We will serve overlooked populations; pediatric and adolescent patients, frail and elderly, and the poorer amongst us. We develop products that improve outcomes without additional suffering because we believe that side effects from treatments of cancers or infections should never be worse than the diseases themselves.

Our Story

AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 47 patents, Dr. Deisher leads a team of scientists dedicated to changing what a diagnosis of cancer, autoimmunity, or chronic infectious disease means to patients and their loved ones. We received FDA IND approval to test our lead product AVM0703 for treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has received permission to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS.

01 NKT

Supercharged Natural Killer T-Cells

Natural killer T cells (NKT) bridge the innate (rapid) and adaptive (long term immunity) immune systems. They love to kill cancer, viruses, and bacteria. AVM’s supercharged NKT are like an elite special forces unit of killers that develop long term memory.

02 Cytotoxic

Supercharged Cytotoxic T-Cells

Cytotoxic T cells kill cancer and infected cells by forcing the cells to commit suicide (apoptosis). AVM supercharged cytotoxic T cells are like another elite special forces unit of killers that develop long term memory.

03 CD11b+ Dendritic

Supercharged CD11b+ Dendritic Cells

AVM supercharged dendritic cells are like early warning scouts. They engulf and chomp up abnormal cells killed by the AVM-NKT cells and present remnants of the dead cells to other lymphocytes for long term memory.

The Future of Immunotherapy

Learn More